PERRIGO Co plc (PRGO) Stock Analysis and Metrics

Perrigo

NYSE: PRGO

$10.09 ▼ -0.01 (-0.10%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.40 Bn

P/E-55.32

P/S0.33

Div. Yield0.11

ROIC (Qtr)-0.12

Total Debt (Qtr)3.63 Bn

Revenue Growth (1y) (Qtr)-7.16

Add ratio to table…

About

Perrigo Company plc is a leading pure play self care company that develops, manufactures and markets high quality health and wellness solutions. The company operates primarily in the over the counter (OTC) self care sector, offering products across categories such as upper respiratory, nutrition, digestive health, pain and sleep aids, oral care, healthy lifestyle, skin care, women's health, vitamins, minerals, and supplements. Perrigo serves consumers mainly in North America and Europe through a mix of store brand and branded offerings.

Perrigo generates revenue by selling store brand products sold under retailers’ private labels and its own branded self care goods to a broad range of customers. Its sales flow through major retail drug, supermarket, and mass merchandise chains, e commerce retailers, wholesalers, and pharmacy chains in Europe. No single product accounts for more than 5% of total revenue, while Walmart contributed 12.9% of consolidated net sales in 2025.

Perrigo holds a leading position as the top store brand private label provider in North America and maintains a strong branded portfolio in Europe. Its competitors include manufacturers such as Dr. Reddy’s Laboratories, LNK International, PL Developments, Aurobindo Pharma, and Sun Pharmaceutical Industries, as well as large consumer health firms like Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer AG, Opella, Philips, Teva, Viatris, and Stada. The company’s competitive advantages stem from a diverse product portfolio, strong research and development capabilities, deep consumer insights, extensive global commercial infrastructure, and a supply chain that leverages scale across multiple dosage forms and geographies.

Perrigo’s customer base comprises major global, national, and regional retail drug stores, supermarkets, and mass merchandise chains, e commerce retailers, wholesalers, and pharmacy networks in Europe. Walmart Inc. is the largest individual customer, representing 12.9% of 2025 consolidated net sales, while the top ten customers together accounted for 47% of total revenue that year.

Investment Thesis

▲ Bull case

Perrigo’s strategic Three-S plan (stabilize, streamline, strengthen) is yielding tangible results that the market is underestimating, particularly in the Specialty Care segment where share gains are outpacing broader category weakness. The company has achieved 270 basis points of U.S. store brand OTC volume share growth in Q1 FY26 alone, with six of seven categories improving and nicotine replacement therapy showing exceptional momentum at 540 basis points year-to-date. This broad-based share expansion reflects the effectiveness of Perrigo’s new category-led operating model, which leverages its scale across 250+ molecules and deep retailer partnerships to drive innovation at the category level—such as the 360-degree approach in nicotine replacement therapy that expands the addressable market beyond traditional quitters to include vapers and dual users. Crucially, Perrigo’s store brand demand generation capability—unique among large-scale suppliers—enables it to partner with retailers to elevate conversations beyond price, driving household penetration where a 1-point increase translates to over $100 million in incremental retail sales. These initiatives are not yet fully reflected in financials due to transitory headwinds but represent a scalable, repeatable growth model with significant upside as category demand normalizes in the second half of FY26.
Perrigo’s capital allocation strategy, bolstered by the recent Dermacosmetics divestiture, is creating underappreciated financial flexibility that will accelerate deleveraging and support higher-margin growth investments. The completed sale of Dermacosmetics for approximately EUR 306 million in upfront cash proceeds is being directed toward debt reduction, with the company having already amended its $1 billion revolving credit facility to extend maturity to 2031 and repay the $421 million Term Loan A, eliminating significant near-term maturities until 2029. This proactive balance sheet management reduces interest expense pressure and enhances financial resilience, especially as the company anticipates lower interest costs in the second half of FY26 from applying divestiture proceeds. Simultaneously, the operational enhancement program delivered over $7 million in cost savings in Q1 FY26 and remains on track for $60–$80 million in annual savings for 2026, with an additional $20–$40 million expected in 2027—efficiencies that are partially offsetting gross margin pressures from volume headwinds and mix shifts. The market is overlooking how these structural improvements in cost base and capital structure will amplify earnings power as sales recovery takes hold, particularly given the company’s guidance that 65–70% of CORE adjusted EPS is expected in the second half of FY26, supported by back-half weighted drivers like consumer-centric innovation (60% of benefit in H2), distribution gains amplified by demand generation, and targeted geographic expansion.
Perrigo’s geographic expansion strategy, particularly in Europe, is generating early wins that signal sustainable topline growth potential beyond the current transitory cough and cold weakness. Despite challenging macroeconomic pressures in Europe, key brands like ellaOne (up 200 basis points value share), Jungle Formula (up 140 basis points), and Physiomer (up 50 basis points) are gaining traction, while seasonal brands such as Compeed are showing strong momentum—achieving 550 basis points of share growth in Italy (reaching 35% share) and 160 basis points in France (approaching 36% share)—driven by focused investment, improved activation, and stronger retailer execution. This performance validates Perrigo’s ability to scale growth through its targeted geographic expansion initiative, which leverages its core strengths in regulatory capability and supply chain to enter new markets with lower risk and faster payback. Importantly, the company currently serves only approximately 5% of global households, indicating a substantial long-term runway for expansion. As these initiatives mature and combine with store brand demand generation and 360-degree innovation, they form a repeatable model for incremental growth that is not yet priced into the stock, especially as Perrigo expects sequential improvement in demand throughout FY26 driven by stabilizing seasonal incidence and inventory rebalancing.

Perrigo’s strategic Three-S plan (stabilize, streamline, strengthen) is yielding tangible results that the market is underestimating, particularly in the Specialty Care segment where share gains are outpacing broader category weakness. The company has achieved 270 basis points of U.S. store brand OTC volume share growth in Q1 FY26 alone, with six of seven categories improving and nicotine replacement therapy showing exceptional momentum at 540 basis points year-to-date. This broad-based share expansion reflects the effectiveness of Perrigo’s new category-led operating model, which leverages its scale across 250+ molecules and deep retailer partnerships to drive innovation at the category level—such as the 360-degree approach in nicotine replacement therapy that expands the addressable market beyond traditional quitters to include vapers and dual users. Crucially, Perrigo’s store brand demand generation capability—unique among large-scale suppliers—enables it to partner with retailers to elevate conversations beyond price, driving household penetration where a 1-point increase translates to over $100 million in incremental retail sales. These initiatives are not yet fully reflected in financials due to transitory headwinds but represent a scalable, repeatable growth model with significant upside as category demand normalizes in the second half of FY26.
Perrigo’s capital allocation strategy, bolstered by the recent Dermacosmetics divestiture, is creating underappreciated financial flexibility that will accelerate deleveraging and support higher-margin growth investments. The completed sale of Dermacosmetics for approximately EUR 306 million in upfront cash proceeds is being directed toward debt reduction, with the company having already amended its $1 billion revolving credit facility to extend maturity to 2031 and repay the $421 million Term Loan A, eliminating significant near-term maturities until 2029. This proactive balance sheet management reduces interest expense pressure and enhances financial resilience, especially as the company anticipates lower interest costs in the second half of FY26 from applying divestiture proceeds. Simultaneously, the operational enhancement program delivered over $7 million in cost savings in Q1 FY26 and remains on track for $60–$80 million in annual savings for 2026, with an additional $20–$40 million expected in 2027—efficiencies that are partially offsetting gross margin pressures from volume headwinds and mix shifts. The market is overlooking how these structural improvements in cost base and capital structure will amplify earnings power as sales recovery takes hold, particularly given the company’s guidance that 65–70% of CORE adjusted EPS is expected in the second half of FY26, supported by back-half weighted drivers like consumer-centric innovation (60% of benefit in H2), distribution gains amplified by demand generation, and targeted geographic expansion.
Perrigo’s geographic expansion strategy, particularly in Europe, is generating early wins that signal sustainable topline growth potential beyond the current transitory cough and cold weakness. Despite challenging macroeconomic pressures in Europe, key brands like ellaOne (up 200 basis points value share), Jungle Formula (up 140 basis points), and Physiomer (up 50 basis points) are gaining traction, while seasonal brands such as Compeed are showing strong momentum—achieving 550 basis points of share growth in Italy (reaching 35% share) and 160 basis points in France (approaching 36% share)—driven by focused investment, improved activation, and stronger retailer execution. This performance validates Perrigo’s ability to scale growth through its targeted geographic expansion initiative, which leverages its core strengths in regulatory capability and supply chain to enter new markets with lower risk and faster payback. Importantly, the company currently serves only approximately 5% of global households, indicating a substantial long-term runway for expansion. As these initiatives mature and combine with store brand demand generation and 360-degree innovation, they form a repeatable model for incremental growth that is not yet priced into the stock, especially as Perrigo expects sequential improvement in demand throughout FY26 driven by stabilizing seasonal incidence and inventory rebalancing.

▼ Bear case

Perrigo’s financial performance remains overly dependent on transitory category dynamics, and the market may be underestimating the persistence of macroeconomic headwinds that could delay the expected second-half recovery in FY26. While management attributes Q1 FY26’s 8.3% CORE net sales decline primarily to softer cough and cold incidence (a 3.5% headwind) and retailer inventory destocking (an additional 3-point headwind), these factors are compounded by ongoing weakness in European markets, where value declined 3.7% and volume 4.4%—trends driven by broader consumption softness in cough, cold, and pain categories within Self Care. The company’s reliance on stabilizing seasonal patterns and lapping prior-year comparisons assumes a return to historical norms, but persistent macroeconomic pressures—particularly in Europe—could suppress consumer spending on discretionary health items longer than anticipated, undermining the thesis that H2 improvement is imminent. Furthermore, the carryover impact of prior-year manufacturing volume headwinds is expected to weigh on All In EPS by approximately $0.60 for the full year, with $0.26 already realized in Q1; if these headwinds persist beyond current estimates due to unresolved supply chain inefficiencies or lingering cost pressures, they could continue to drag on margins and profitability well into 2027, making the transition year narrative overly optimistic.
Perrigo’s strategic initiatives, while promising, face execution risks that could limit their ability to drive meaningful top-line growth, particularly in the Specialty Care and Infant Formula segments where progress remains inconsistent and contingent on external factors. Although the company highlights share gains in women’s health (e.g., ellaOne up 200 basis points) and niche brands like Opill (up 40 basis points) and Mederma Cold Sore (up 180 basis points), these improvements are occurring against a backdrop of declining overall category consumption, raising questions about whether share gains are truly reflective of underlying demand or merely a function of taking share from a shrinking pie. Moreover, the Infant Formula segment—despite modest 2% net sales growth in Q1 FY26 driven by contract manufacturing—remains under strategic review, with management acknowledging ongoing evaluations of optimization, partnerships, and divestments, signaling uncertainty about its long-term role in the portfolio. The operational enhancement program, while on track for $60–$80 million in savings for 2026, is still in early stages, and its benefits are being partially offset by unfavorable mix and lower sales volumes, as evidenced by CORE adjusted gross margin declining 160 basis points to 39.2%. Without clear evidence that these initiatives can generate sustainable, profitable growth independent of category tailwinds, the market may be overestimating their near-term impact.
Perrigo’s capital allocation priorities, particularly its focus on debt reduction using Dermacosmetics proceeds, may come at the expense of necessary reinvestment in growth engines, creating a potential misalignment between short-term balance sheet strength and long-term value creation. While the company has successfully reduced near-term debt maturities by repaying the $421 million Term Loan A and extending its revolver to 2031, the aggressive use of divestiture proceeds for deleveraging could limit funding for critical investments in innovation, geographic expansion, and demand generation programs—areas management itself identifies as key drivers for H2 FY26 recovery. The emphasis on debt reduction, while prudent in a volatile environment, risks starving the very initiatives that are supposed to power the second-half recovery, such as consumer-centric innovation (where 60% of the benefit is expected in H2) and targeted geographic expansion. Additionally, the company’s guidance that only 30–35% of CORE adjusted EPS is expected in H1 FY26 implies a heavy reliance on H2 performance, yet there is limited visibility into whether the assumed demand stabilization will materialize on schedule. If growth initiatives fail to deliver as expected or if macroeconomic headwinds intensify, Perrigo could find itself with a strengthened balance sheet but stagnant top-line growth, undermining investor confidence in its ability to generate sustained shareholder value.

Perrigo’s financial performance remains overly dependent on transitory category dynamics, and the market may be underestimating the persistence of macroeconomic headwinds that could delay the expected second-half recovery in FY26. While management attributes Q1 FY26’s 8.3% CORE net sales decline primarily to softer cough and cold incidence (a 3.5% headwind) and retailer inventory destocking (an additional 3-point headwind), these factors are compounded by ongoing weakness in European markets, where value declined 3.7% and volume 4.4%—trends driven by broader consumption softness in cough, cold, and pain categories within Self Care. The company’s reliance on stabilizing seasonal patterns and lapping prior-year comparisons assumes a return to historical norms, but persistent macroeconomic pressures—particularly in Europe—could suppress consumer spending on discretionary health items longer than anticipated, undermining the thesis that H2 improvement is imminent. Furthermore, the carryover impact of prior-year manufacturing volume headwinds is expected to weigh on All In EPS by approximately $0.60 for the full year, with $0.26 already realized in Q1; if these headwinds persist beyond current estimates due to unresolved supply chain inefficiencies or lingering cost pressures, they could continue to drag on margins and profitability well into 2027, making the transition year narrative overly optimistic.
Perrigo’s strategic initiatives, while promising, face execution risks that could limit their ability to drive meaningful top-line growth, particularly in the Specialty Care and Infant Formula segments where progress remains inconsistent and contingent on external factors. Although the company highlights share gains in women’s health (e.g., ellaOne up 200 basis points) and niche brands like Opill (up 40 basis points) and Mederma Cold Sore (up 180 basis points), these improvements are occurring against a backdrop of declining overall category consumption, raising questions about whether share gains are truly reflective of underlying demand or merely a function of taking share from a shrinking pie. Moreover, the Infant Formula segment—despite modest 2% net sales growth in Q1 FY26 driven by contract manufacturing—remains under strategic review, with management acknowledging ongoing evaluations of optimization, partnerships, and divestments, signaling uncertainty about its long-term role in the portfolio. The operational enhancement program, while on track for $60–$80 million in savings for 2026, is still in early stages, and its benefits are being partially offset by unfavorable mix and lower sales volumes, as evidenced by CORE adjusted gross margin declining 160 basis points to 39.2%. Without clear evidence that these initiatives can generate sustainable, profitable growth independent of category tailwinds, the market may be overestimating their near-term impact.
Perrigo’s capital allocation priorities, particularly its focus on debt reduction using Dermacosmetics proceeds, may come at the expense of necessary reinvestment in growth engines, creating a potential misalignment between short-term balance sheet strength and long-term value creation. While the company has successfully reduced near-term debt maturities by repaying the $421 million Term Loan A and extending its revolver to 2031, the aggressive use of divestiture proceeds for deleveraging could limit funding for critical investments in innovation, geographic expansion, and demand generation programs—areas management itself identifies as key drivers for H2 FY26 recovery. The emphasis on debt reduction, while prudent in a volatile environment, risks starving the very initiatives that are supposed to power the second-half recovery, such as consumer-centric innovation (where 60% of the benefit is expected in H2) and targeted geographic expansion. Additionally, the company’s guidance that only 30–35% of CORE adjusted EPS is expected in H1 FY26 implies a heavy reliance on H2 performance, yet there is limited visibility into whether the assumed demand stabilization will materialize on schedule. If growth initiatives fail to deliver as expected or if macroeconomic headwinds intensify, Perrigo could find itself with a strengthened balance sheet but stagnant top-line growth, undermining investor confidence in its ability to generate sustained shareholder value.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password